Clinical Comparison of Cefuroxime Axetil With Cefixime in the Treatment of Acute Bronchitis

Arthur, Margaret; McAdoo, Michael A.; Guerra, Javier Miguel Martín; Maloney, Robert; McCluskey, Dennis; Giguere, Gregory; Gómez, G Calzado; Collins, Jeffrey J.

doi:10.1097/00045391-199609000-00004

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical cure or improvement rate reported in these studies (82%) with the 5-day regimen of cefuroxime axetil at 250 mg twice daily is similar to that observed in previous clinical comparisons of 10-day treatments for acute bronchitis or acute exacerbations of chronic bronchitis with cefuroxime axetil and cefaclor (90 to 100% versus 90 to 100%) (27,33), cefuroxime axetil and cefadroxil (89 to 98% versus 72 to 94%) (3,19), and cefuroxime axetil and cefixime (88% versus 91%) (2).…”

Section: Discussionsupporting

confidence: 83%

Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis

Henry

Ruoff

Rhudy

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Five hundred thirty-seven patients were enrolled in two independent, investigator-blinded, multicenter, randomized clinical trials comparing the clinical and bacteriologic efficacies and the safety of 5-or 10-day treatment with cefuroxime axetil with those of 10-day treatment with amoxicillin-clavulanate in the treatment of secondary bacterial infections of acute bronchitis. Patients received either 5 or 10 days of treatment (n ‫؍‬ 177 in each group) with cefuroxime axetil at 250 mg twice daily or 10 days of treatment (n ‫؍‬ 183) with amoxicillinclavulanate at 500 mg three times daily. Patients in the cefuroxime axetil (5 days) group received placebo on days 6 to 10. Bacteriologic assessments were based on sputum specimen cultures obtained preceding and, when possible, following treatment. Organisms were isolated from the pretreatment sputum specimens of 242 of 537 (45%) patients, with the primary pathogens being Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Staphylococcus aureus (28, 25, 13, 9, and 8% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 87% (52 of 60), 91% (53 of 58), and 86% (60 of 70) of bacteriologically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. A satisfactory clinical outcome (cure or improvement) was achieved in 82% (107 of 130), 86% (117 of 136), and 83% (130 of 157) of the clinically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. Treatment with amoxicillin-clavulanate was associated with a significantly higher incidence of drug-related adverse events than was treatment with cefuroxime axetil for either 5 or 10 days (P ‫؍‬ 0.001), primarily reflecting a higher incidence of drug-related gastrointestinal adverse events (37 versus 19 and 15%, respectively; P < 0.001), particularly diarrhea and nausea. These results indicate that treatment with cefuroxime axetil at 250 mg twice daily for 5 days is as effective as treatment for 10 days with either the same dose of cefuroxime axetil or amoxicillin-clavulanate at 500 mg three times daily in patients with acute bronchitis. In addition, treatment with cefuroxime axetil for either 5 or 10 days is associated with significantly fewer gastrointestinal adverse events, particularly diarrhea and nausea, than is 10-day treatment with amoxicillin-clavulanate.

show abstract

Section: Discussionsupporting

confidence: 83%

Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis

Henry

Ruoff

Rhudy

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Ceftazidime is used to treat infections of lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal ( Shirley, 2018 ). Cefixime is prescribed for bacterial infections of the chest, ears, urinary tract, and throat (tonsilitis and pharyngitis), uncomplicated gonorrhea, upper and lower respiratory tract infections, acute otitis media, and gonococcal urethritis ( Quintiliani, 1996 , Bluestone, 1993 , Arthur et al, 1996 ). Ceftazidime has been identified as an inhibitor towards the wild type SARS-CoV-2 S proein-ACE2 interactions in recent studies ( Lin et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

Cui²,

Du³

et al. 2022

Virus Research

View full text Add to dashboard Cite

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age

Lucero

Dulalia

Parreno

et al. 2004

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Clinical Comparison of Cefuroxime Axetil With Cefixime in the Treatment of Acute Bronchitis

Cited by 9 publications

References 0 publications

Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis

Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age

Contact Info

Product

Resources

About